Percutaneous transluminal angioplasty of the abdominal aorta.

M. Hallisey,S. Meranze,B. C. Parker,K. Rholl,W. J. Miller,B. Katzen,A. van Breda

DOI: https://doi.org/10.1016/S1051-0443(94)71582-7

IF: 3.682

1994-09-01

Journal of Vascular and Interventional Radiology

Abstract:

What problem does this paper attempt to address?

Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review

Hio Fong Leong,Wen-Hui Wang,Fen Peng

DOI: https://doi.org/10.5114/ada.2024.141128

Abstract:Introduction: Palmoplantar pustulosis (PPP) is a complex inflammatory skin disease. Currently, no standardized treatments exist, and traditional systemic therapies often display limited effectiveness and substantial adverse effects. Biologics, however, have shown potential for enhanced clinical outcomes in psoriasis patients, thereby prompting this investigation into their applicability in PPP treatment. Aim: This study constitutes the first comprehensive review to assess the effectiveness and underlying mechanisms of biologics for PPP. Material and methods: We conducted a PubMed search to identify studies on biologics for PPP from 1992 onward. The review focused on assessing the efficacy of biologics targeting cytokines like IL-1, IL-8, IL-17, IL-12/23, IL-36, and TNF-α. Results: Biologics for PPP are generally less effective than for psoriasis. Secukinumab and guselkumab, IL-17 and IL-23 inhibitors respectively, have shown better results compared to other biologics in trials. However, the effectiveness of other biologics remains uncertain due to limited data. Conclusions: More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.
Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis

RuiYuan Xia,ZiYue Diao,DanDan Chen,YuFei Wang,ChaoJing Zhou,YaMei Gao,ZhiQiang Yin

DOI: https://doi.org/10.1016/j.intimp.2024.111716

IF: 5.714

2024-02-29

International Immunopharmacology

Abstract:Background The comparative efficacy of anti-IL (interleukin)-17A biological agents in palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are not well established. Objective To investigate the efficacy of different dosage regimens of anti-IL-17A biological agents compared with placebo in PP and PPP. Methods A literature search was conducted in PubMed, clinicaltrials.gov , and Embase. Meta-analysis was performed for all outcomes of randomized controlled trials, while network meta-analysis was only performed for the primary outcome. Results In total, 21 articles exploring the efficacy of 5 treatment options were included, 4 cohort studies were also reviewed. Meta-analysis demonstrated a statistically significant difference favoring anti-IL-17A biological agents versus placebo (OR = 6.84, 95 %[CI] [5.34, 8.76]). On-label secukinumab was identified as the most effective treatment option for patients with PP (OR = 33.50, 95 %[CI] [4.37,256.86]). PPP treated with secukinumab 300 mg showed benefit in terms of PPPASI 75 responses over 52 weeks. Conclusion IL-17A biological agents had better PP disease clearance compared with placebo and on-label secukinumab was identified as the most effective treatment option for PP patients. Secukinumab 300 mg showed benefit for PPP patients.

pharmacology & pharmacy,immunology
A systematic review of recent randomized controlled trials for palmoplantar pustulosis

Miranda K. Branyiczky,Shahnawaz Towheed,Tiago Torres,Ronald Vender

DOI: https://doi.org/10.1080/09546634.2024.2414048

2024-10-12

Journal of Dermatological Treatment

Abstract:Background: Palmoplantar pustulosis (PPP) is a chronic inflammatory condition, that leads to significant functional impairment and reduced quality of life. Despite its low incidence, treatment options are diverse and often ineffective, necessitating a review of recent therapeutic advances.

dermatology
Efficacy and Safety of Benvitimod in Patients With Palmoplantar Pustulosis: An Open‐Label, Multicenter, Prospective Study

Guangping Wang,Shuai Zhang,Huimin Yan,Fang Qi,Bingxin Zhang,Yan Li,Hongmei Wang,Jingna Song,Siyao Wang,Sanwu Zeng,Liming Ji

DOI: https://doi.org/10.1155/2024/8829762

2024-10-24

Dermatologic Therapy

Abstract:Palmoplantar pustulosis (PPP) is often considered as pustular psoriasis of extremities. Benvitimod has been approved for mild to moderate psoriasis. We thus designed this study to evaluate the efficacy and safety of benvitimod for treating PPP. Of 47 PPP patients recruited from 4 hospitals, 40 finished 8 weeks visit and completed 4 weeks safety follow‐up visit. The Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) and Dermatology Life Quality Index (DLQI) scores fell continuously. At week 8, mean ± SD PPPASI and DLQI were 3.39 ± 3.86 (p < 0.0001) and 2.49 ± 3.34 (p < 0.0001), respectively. At week 8, 70% (28/40) achieved PPPASI‐50 response, 35% (14/40) achieved PPPASI‐75 response, and 17.5% (7/40) achieved PPPASI‐90 response. Relapse occurred in 7.5% (3/40) of the patients. Of 47 patients enrolled, self‐reported compliance was 12.77% (6/47). Common drug‐related adverse events (5/47) included xerosis cutis. Only one patient's disease progressed during treatment. Our study demonstrated the efficacy and safety of benvitimod.

dermatology
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

Magdalena Misiak-Galazka,Joanna Zozula,Lidia Rudnicka

DOI: https://doi.org/10.1007/s40257-020-00503-5

2020-02-01

American Journal of Clinical Dermatology

Abstract:Palmoplantar pustulosis (PPP) is a chronic, recurrent skin disease belonging to the spectrum of psoriasis. It is characterized by an eruption of sterile pustules on the palms and soles. Recent studies in PPP have focused on genetic differences between pustular phenotypes and the role of the innate immunological system and the microbiome in the etiopathogenesis of the disease. Mutations in <em class="EmphasisTypeItalic">IL36RN</em> (a major predisposing factor for generalized pustular psoriasis) were found in selected patients with PPP and were associated with earlier disease onset. Studies have shown that the interleukin (IL)-17 and IL-36 pathways might be involved in the pathogenesis of PPP. A microbiome has been demonstrated in the vesicopustules of PPP, and an abundance of <em class="EmphasisTypeItalic">Staphylococcus</em> appears to be increased by smoking. Improved understanding of the underlying etiopathogenesis of PPP has led to advances in treatment options, and targeted therapies for PPP have been evaluated or are under evaluation against more than 12 molecules in ongoing clinical trials. These targets include CXCR2 (IL-8 receptor type B), granulocyte colony-stimulating factor receptor, IL-1 receptor, IL-8, IL-12, IL-23, IL-17A, IL-17 receptor, IL-36 receptor, phosphodiesterase-4, and tumor necrosis factor-α.
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial

Yukari Okubo,Satomi Kobayashi,Masamoto Murakami,Shigetoshi Sano,Natsuko Kikuta,Yoshiumi Ouchi,Tadashi Terui

DOI: https://doi.org/10.1007/s40257-024-00876-x

Abstract:Background: Palmoplantar pustulosis (PPP), a refractory skin disease characterized by repeated eruptions of sterile pustules and vesicles on palms and/or soles, involves interleukin-17 pathway activation. Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, is being investigated for use in PPP treatment. Objective: The aim was to assess the efficacy and safety of brodalumab in Japanese PPP patients with moderate or severe pustules/vesicles. Methods: A phase 3, randomized, double-blind, placebo-controlled trial was conducted between July 2019 and August 2022, at 41 centers in Japan. Patients aged 18-70 years with a diagnosis of PPP for ≥ 24 weeks, a PPP Area Severity Index (PPPASI) score of ≥ 12, a PPPASI subscore of pustules/vesicles of ≥ 2, and inadequate response to therapy were included. Participants were randomized 1:1 to receive brodalumab 210 mg or placebo, subcutaneously (SC) at baseline, weeks 1 and 2, and every 2 weeks (Q2W) thereafter until week 16. Changes from baseline to week 16 in the PPPASI total score (primary endpoint) and other secondary skin-related endpoints and safety endpoints were assessed. Results: Of the 126 randomized patients, 50 of 63 in the brodalumab group and 62 of 63 in the placebo group completed the 16-week period. Reasons for discontinuation were adverse event (n = 6), withdrawal by patient/parent/guardian (n = 3), progressive disease (n = 3), and lost to follow-up (n = 1) in the brodalumab group and Good Clinical Practice deviation (n = 1) in the placebo group. Change from baseline in the PPPASI total score at week 16 was significantly higher (p = 0.0049) with brodalumab (least-squares mean [95% confidence interval {CI}] 13.73 [10.91-16.56]) versus placebo (8.45 [5.76-11.13]; difference [95% CI] 5.29 [1.64-8.94]). At week 16, brodalumab showed a trend of rapid improvement versus placebo for PPPASI-50/75/90 response (≥ 50%/75%/90% improvement from baseline) and Physician's Global Assessment 0/1 score: 54% versus 24.2%, 36.0% versus 8.1%, 16.0% versus 0.0%, and 32.0% versus 9.7%, respectively. Infection was the dominant treatment-emergent adverse event (TEAE); the commonly reported TEAEs were otitis externa (25.4%/1.6%), folliculitis (15.9%/3.2%), nasopharyngitis (14.3%/4.8%), and eczema (14.3%/12.9%) in the brodalumab/placebo groups, respectively. The severity of most TEAEs reported was Grade 1 or 2 and less frequently Grade ≥ 3. Conclusions: Brodalumab SC 210 mg Q2W demonstrated efficacy in Japanese PPP patients. The most common TEAEs were mild infectious events. Trial registration: NCT04061252 (Date of Trial Registration: August 19, 2019).
Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis

Bai-lin Chen,Qian-wei Liu,Xiao-wan Dong,Yan-ping Bai

DOI: https://doi.org/10.3389/fimmu.2024.1462158

IF: 7.3

2024-10-14

Frontiers in Immunology

Abstract:Introduction: Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening auto-inflammatory disease. Currently, there are no consensus-based guidelines or universally accepted treatments. Biologics represent a potential therapeutic option. This study systematically assessed the efficacy and safety of biologics in GPP. Methods: Relevant studies from three databases were systematically searched until June 28, 2024. Statistical information, including the single-arm proportion rate of the outcomes and 95% confidence intervals (CIs), was analyzed to determine treatment effects. Heterogeneity was assessed using I2 values, and subgroup analyses were performed based on drug targets and treatment durations. Data were quantitatively synthesized using a random-effects meta-analysis. Analyses were performed using R statistical software version 4.4.0. Results: A total of 329 patients from 16 studies were included. The proportion of responders treated with IL-36 inhibitors and IL-17 inhibitors is higher than those treated with TNF-α inhibitors and IL-23 inhibitors. IL-36 inhibitors appear to achieve the highest response rates between 4 and 8 weeks, while IL-17 inhibitors, TNF-alpha inhibitors, and IL-23 inhibitors show a gradual increase in response rates up to 12 weeks. IL-36 inhibitors achieve a 40% (95% CI: 27%-54%) GPPASI75 response rate and a 55% (95% CI: 41%-68%) GPPGA (0,1) response rate within 2 weeks, significantly outperforming other biologics. The recurrence rates of GPP within 52 weeks, ranked from highest to lowest, are: IL-36 inhibitors (21% [95% CI: 9%-28%]), TNF-alpha inhibitors (20% [95% CI: 2%-46%]), IL-17 inhibitors (15% [95% CI: 1%-37%]), and IL-23 inhibitors (5% [95% CI: 0%-29%]). Additionally, 6% (95% CI: 1%-11%) of patients experienced severe adverse events. Discussion: This meta-analysis highlights the efficacy and safety of biologics in patients with GPP, offering valuable evidence to guide future clinical practice. IL-36 inhibitors show a faster and more substantial clinical response in GPP compared to other biologics. Further research is necessary to assess their role in specific subpopulations and to evaluate their potential long-term effects on flare prevention.

immunology
Efficacy of Dupilumab in Palmoplantar Pustulosis Treatment Highlights the Role of Th2 Inflammation.

Yu-Xin Zheng,Xi-Bei Chen,Zhao-Yuan Wang,Sui-Qing Cai,Min Zheng,Li Fang Koh,John E. Common,Xiao-Yong Man

DOI: https://doi.org/10.1111/all.16019

IF: 12.4

2024-01-01

Allergy

Abstract:Palmoplantar pustulosis is a chronic, recurrent skin disorder characterized by sterile pustules and erythematous scaling on the palms and soles. In our study, dupilumab treatment showed efficacy and safety in PPP patients, potentially resulting from PPP patients' serum Th2 signatures and the similarities between PPP and atopic dermatitis based on serum Olink proteomics.image
Involvement of Molecular Mechanisms between T/B Cells and IL-23: From Palmoplantar Pustulosis to Autoimmune Diseases

A. Yoshizaki-Ogawa,K. Miyagawa,Atsushi Enomoto,S. Sato,A. Yoshizaki,T. Fukasawa

DOI: https://doi.org/10.3390/ijms23158261

IF: 5.6

2022-07-27

International Journal of Molecular Sciences

Abstract:Palmoplantar pustulosis (PPP) is a disease that causes recurrent blisters and aseptic pustules on the palms and soles. It has been suggested that both innate and acquired immunity are involved. In particular, based on the tonsils and basic experiments, it has been assumed that T and B cells are involved in its pathogenesis. In addition, the results of clinical trials have suggested that IL-23 is closely related to the pathogenesis. This review describes PPP and the genetic background, the factors involved in the onset and exacerbation of disease and its relation to the molecular mechanism. In addition, we describe the usefulness of biological therapy and its implications in relation to the importance in pathology, the pathogenesis of PPP, the importance of the role of the IL-23–Th17 axis and IL-36 in PPP. Furthermore, we describe an animal experimental model of PPP, the efficacy and mechanism of action of guselkumab, an anti-IL-23 antibody, the latest research, and finally the possibility for it to be effective for other autoimmune diseases.

Biology,Medicine
Interventions for chronic palmoplantar pustulosis.

Grace Obeid,Giao Do,Lisa Kirby,Carolyn Hughes,Emilie Sbidian,Laurence Le Cleach

DOI: https://doi.org/10.1002/14651858.CD011628.pub2

IF: 8.4

2020-01-21

Cochrane Database of Systematic Reviews

Abstract:Palmoplantar pustulosis is a chronic inflammatory disease in which sterile, relapsing pustules appear on the palms and soles, possibly in conjunction with other symptoms. The previous Cochrane Review on this topic was published in 2006, before biological treatments were extensively used. To assess the effects of interventions for chronic palmoplantar pustulosis to induce and maintain complete remission. We searched the following databases up to March 2019: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of the included studies for further references to relevant randomised controlled trials (RCTs). We considered RCTs including people with palmoplantar pustulosis or chronic palmoplantar pustular psoriasis assessing topical therapy, systemic therapy, combinations of topical or systemic therapies, or non‐pharmacological therapies compared with placebo, no intervention, or each other. We used standard methodological procedures expected by Cochrane. Our outcomes included 'Proportion of participants cleared or almost cleared', 'Proportion of participants with adverse effects serious or severe enough to cause withdrawal', 'Proportion of participants with at least 50% improvement in disease severity', and 'Proportion of participants with adverse effects'. We included 37 studies (1663 participants; mean age 50 years (range 34 to 63); 24% males). These studies reported condition severity differently. Around half of the included trials stated the setting (hospitals, community clinics, or both). More than half of the studies were at high risk of bias in at least one domain. Our included studies assessed mainly systemic treatments (retinoids, ciclosporin, biologics, etretinate + PUVA (combination of psoralens and long‐wave ultraviolet radiation) therapy combined, and antibiotics), but also topical treatments (dermocorticoids, vitamin D) and phototherapy (PUVA, ultraviolet A1 (UVA1)). Other interventions were assessed by single studies. The most common comparator was placebo. All results presented in this abstract were assessed in the short term (mean treatment duration was 11 weeks (range 8 to 24 weeks)) and are based on participants with chronic palmoplantar pustulosis. All outcome time point measurements were taken from baseline and assessed at the end of treatment. Short‐term and long‐term outcomes were defined as measurement up to 24 weeks after randomisation and between 24 and 104 weeks after randomisation, respectively. One trial (188 participants) assessed the topical vitamin D derivative maxacalcitol versus placebo and found that maxacalcitol may be more effective than placebo in achieving clearance (risk ratio (RR) 7.83, 95% confidence interval (CI) 1.85 to 33.12; low‐quality evidence), and the risk of adverse effects (such as mild local irritation, pruritus, and haematological or urinary test abnormalities) is probably similar in both groups (RR 0.87, 95% CI 0.64 to 1.19; moderate‐quality evidence). Severity was not reported. Two trials (49 participants) assessed PUVA therapy versus placebo or no treatment, providing very low‐quality evidence. Adverse effects were reported with oral PUVA (including nausea, ankle swelling, and non‐purulent conjunctivitis) and with local PUVA (including blistering, erythema, and pruritus). With regard to the systemic retinoid alitretinoin, one trial (33 participants; moderate‐quality evidence) showed that alitretinoin probably makes little or no difference in reducing severity when compared to placebo (RR 0.69, 95% CI 0.36 to 1.30). A similar number of adverse events were reported in both treatment groups, including headache, cheilitis, nausea, arthralgia, and nasopharyngitis (RR 0.84, 95% CI 0.61 to 1.17). Clearance was not reported. There may be little or no difference between etanercept and placebo in achieving clearance (RR 1.64, 95% CI 0.08 to 34.28; 1 study; 15 participants; low‐quality evidence); however, the 95% CI was very wide, showing there may be a difference between groups. Severity was not measured. More patients treated with placebo may achieve reduced severity than those treated with ustekinumab, but the wide 95% CI indicates there might be little or no difference between groups and there might be greater effect with ustekinumab (RR 0.48, 95% CI 0.11 to 2.13; 1 study; 33 participants; low‐quality evidence). Clearance was not reported. It is uncertain whether guselkumab increases clearance when compared to placebo (2 studies; 154 participants) because the quality of evidence is very low, but guselkumab probably better reduces disease severity (RR 2.88, 95% CI 1.24 to 6.69; 1 study; 49 participants; moderate‐quality evidence). Secukinumab is probably superior to placebo in reducing severity (RR 1.55, 95% CI 1.02 to 2.35; 1 study; 157 participants; moderate‐quality evidence), but our clearance outcome was not -Abstract Truncated-

medicine, general & internal
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search

Lluís Puig,Hideki Fujita,Diamant Thaçi,Min Zheng,Ana Cristina Hernandez Daly,Craig Leonardi,Mark G Lebwohl,Jonathan Barker

DOI: https://doi.org/10.1007/s13555-024-01230-z

2024-08-01

Abstract:Generalized pustular psoriasis (GPP) is a rare, chronic and potentially life-threatening autoinflammatory skin disease characterized by widespread eruption of sterile pustules, with or without systemic inflammation. GPP can significantly reduce patients' quality of life (QoL). Several therapeutic approaches have been described in the literature, but there is no consensus on optimal treatment. In this review, we summarize published literature on efficacy, safety and QoL outcomes associated with current treatment of GPP with both approved and non-approved products. Embase and MEDLINE databases were searched (1980-September 2023). A search protocol was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered on the PROSPERO database (CRD42021215437). Details on publication, population, intervention, efficacy, safety and QoL were captured and checked by independent reviewers. In total, 118 publications were included, with only 19% of publications reporting on the results of clinical trials. Treatment modalities reported for GPP included non-biologic systemic therapies such as retinoids, cyclosporine and methotrexate, topical agents, biologics and small molecules, among others. Results were highly heterogeneous and methodological quality was very low, with only the interleukin-36R inhibitor spesolimab reporting results from placebo-controlled randomized trials; based on this, spesolimab is now approved for GPP treatment in regions including the USA, Japan, China, the EU and several other countries. Some other biologics are approved exclusively in Japan and Taiwan for the treatment of GPP based on open-label studies with small patient numbers in lieu of double-blind studies. Non-standardization of clinical outcomes across studies remains a major hurdle in reaching a consensus on optimal treatment. However, recently trials have been conducted using well-defined, disease-specific endpoints to evaluate GPP-targeted treatments, which will hopefully advance patient care. In conclusion, this review highlights the need for prospective randomized studies with GPP-specific endpoints to determine the optimal treatment strategy.
The differential diagnosis of diabetic retinopathy.

G. M. Haik,L. A. Breffeilh,M. Harrington

1950-09-09

Abstract:
Cytogenetic monitoring in CML patients treated with BMT.

G. Rosti,A. Zaccaria,N. Testoni,B. Celso,G. Bandini,A. Tassinari,L. Albertazzi,C. Miggiano,S. Tura,M. Sessarego

1989-12-01

Bone Marrow Transplantation

Abstract:
Recent advances in palmoplantar pustulosis

Alexandra Maria Giovanna Brunasso,Cesare Massone

DOI: https://doi.org/10.12703/r/10-62

2021-07-27

Faculty Reviews

Abstract:Palmoplantar pustulosis (PPP) is a chronic inflammatory condition where crops of sterile pustules with erythematous keratotic lesions causing bleeding and pain appear on the palms and soles. Recently, the European Rare and Severe Expert Network considered PPP as a variant of pustular psoriasis with or without psoriasis vulgaris. The prevalence of PPP varies from 0.050 to 0.12%. PPP occurs more frequently in women and the highest prevalence occurred between the ages of 50 and 69 years. Nail psoriasis seems to be frequent in PPP, ranging from 30 to 76%, and psoriatic arthritis in 8.6 to 26% of PPP patients. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome and pustulotic arthro-osteitis are considered PPP-associated disorders. PPP has been reported with other co-morbidities such as psychiatric disorders, thyroid-associated disease, altered calcium homeostasis, gluten sensitivity diabetes, obesity, and dyslipidemia, but larger studies are required to prove such associations. Environmental exacerbating factors might contribute to the onset or worsening of PPP such as cigarette smoking, stress, focal infections, metal allergies, and drug intake. Genetic predisposition plays an important role in PPP. In PPP, both the innate and the adaptive immune systems are activated. The acrosyringeal expression of IL-17 has been demonstrated, indicating that the eccrine sweat gland is an active component of the skin barrier and an immune-competent structure. Increased levels of several inflammatory molecules, including IL-8, IL-1α, IL-1β, IL-17A, IL-17C, IL-17D, IL-17F, IL-22, IL-23A, and IL-23 receptor, have been detected in PPP biopsies. Increased serum levels of TNF-α, IL-17, IL-22, and IFN-γ have been detected in patients with PPP in comparison to healthy subjects, suggesting a similar inflammatory pattern to psoriasis vulgaris. Oral and tonsillar infections serve as trigger factors for PPP. Long-term therapy is required for many patients, but high-quality data are limited, contributing to uncertainty about the ideal approach to treatment.
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis

I-Hsin Huang,Po-Chien Wu,Hsien-Yi Chiu,Yu-Huei Huang

DOI: https://doi.org/10.1007/s40257-024-00849-0

2024-03-06

American Journal of Clinical Dermatology

Abstract:The comparative efficacy of biologics and small-molecule inhibitors in treating palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) remains uncertain.

dermatology
Directivity Enhancement and Spurious Radiation Suppression in Leaky-Wave Antennas Using Inductive Grid Metasurfaces

D. Blanco,E. Rajo-Iglesias,S. Maci,N. Llombart

DOI: https://doi.org/10.1109/TAP.2014.2387422

IF: 5.7

2015-01-05

IEEE Transactions on Antennas and Propagation

Abstract:Fabry-Perot antennas (FPA) achieve high broadside directivity due to the simultaneous excitation of a pair of nearly degenerate TE/TM leaky-wave modes using a partially-reflecting surface on top of a ground plane. This partially-reflecting surface can be obtained using a dielectric superstrate or via a capacitive or inductive metasurface (MTS). By using an equivalence between the conventional dielectric superstrate and the MTS-based structures in terms of the dominant TE/TM modes, we show that the use of inductive grid MTSs leads to a directivity enhancement. A higher roll-of in the radiation patterns is achieved as a result of the intrinsic suppression of the spurious TM0 leaky wave mode. This suppression is mathematically demonstrated and validated with full-wave simulations. The achieved improvement in more than 1 dB for inductive strip grid based MTS with respect to dielectric based super-layers, for the same frequency band of 2.5%, is verified with measurements. Two prototypes, with the dielectric superlayer and inductive strip grid based MTS, have been fabricated and measured supporting the claim of this work.
Successful Treatment of Secukinumab-Resistant Palmoplantar Pustulosis by Dupilumab: A Case Report.

Yu-Xin Zheng,Min Zheng,Sui-Qing Cai

DOI: https://doi.org/10.1111/dth.15781

2022-01-01

Dermatologic Therapy

Abstract:Dermatologic TherapyVolume 35, Issue 11 e15781 LETTER Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author First published: 20 August 2022 https://doi.org/10.1111/dth.15781 Funding information: This study was funded by the grant from the National Natural Science Foundation of China (NFSC) (82073426). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: recent advances in Etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020; 21(3): 355-370. 2Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086): 2287-2303. 3Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019; 80(5): 1344-1352. 4Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(7):e574-e576. 5Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2021; 86(3): 708-709. 6Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like eruption triggered by Dupilumab therapy. Dermatitis. 2021; 32(6): e147-e148. 7Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019; 44(3): e49-e50. 8McCluskey D, Benzian-Olsson N, Mahil SK, et al. Single-cell analysis implicates Th17 to Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;S0091-6749(22)00624-8. Volume35, Issue11November 2022e15781 ReferencesRelatedInformation
308‐nm excimer light is effective for palmoplantar pustulosis regardless of the presence or absence of focal infection: Single‐center real‐world experience of treatment for palmoplantar pustulosis

Yoshiko Niimura,Masahiro Kamata,Takeko Ishikawa,Mayumi Nagata,Makoto Ito,Ayu Watanabe,Shota Egawa,Hideaki Uchida,Azusa Hiura,Saki Fukaya,Kotaro Hayashi,Atsuko Fukuyasu,Takamitsu Tanaka,Yayoi Tada

DOI: https://doi.org/10.1111/1346-8138.17191

IF: 3.468

2024-03-15

The Journal of Dermatology

Abstract:Palmoplantar pustulosis (PPP) is relatively rare and recognition of PPP is different in different countries. Therefore, real‐world data are limited. Local phototherapy for the palms and the soles is commonly used to treat PPP due to tolerable safety. However, data on the effectiveness of 308‐nm excimer light are limited. In our study, we retrospectively investigated the effectiveness of treatments for PPP, especially phototherapy (308‐nm excimer light), in our department. In addition, we examined whether smoking status and focal infection affected responsiveness to treatment of PPP. Patients who were diagnosed with PPP by board‐certified dermatologists and visited our hospital from April 2015 to August 2018 were analyzed in this study. We collected data on PPP area severity index (PPPASI) before treatment. We also collected data on PPPASI in May to August 2018 as "after treatment" from all patients. Patients who received any treatment for less than 3 months were excluded. Nineteen patients (16 women and three men) were analyzed in this study. In patients treated with phototherapy (n = 12), PPPASI significantly decreased from a mean ± SD of 16.5 ± 10.3 to 4.5 ± 3.6 (p = 0.004), whereas it did not in patients treated without phototherapy (n = 7). Patients who quit smoking showed a significant decrease in PPPASI after treatment (16.8 ± 12.7 to 2.4 ± 2.9, p = 0.008). Regarding focal infection, in patients treated without phototherapy, the reduction rate of PPPASI was significantly lower in patients with focal infection than in those without focal infection (17.7 ± 21.5%, 71.1 ± 19.3%, p = 0.035), indicating that focal infection is associated with intractability. Meanwhile, in patients treated with phototherapy, PPPASI decreased regardless of the presence or absence of focal infection. In conclusion, our study demonstrated the effectiveness of local phototherapy consisting of 308‐nm excimer light, regardless of focal infection. Patients who quit smoking were responsive to any treatment, indicating the importance of smoking cessation.

dermatology
Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study

Yukari Okubo,Tadashi Terui,Satomi Kobayashi,Shigetoshi Sano,Akimichi Morita,Shinichi Imafuku,Yayoi Tada,Masatoshi Abe,Masafumi Yaguchi,Takeshi Kimura,Junichiro Shimauchi,Wendy Zhang,Hamid Amouzadeh,Masamoto Murakami

DOI: https://doi.org/10.1007/s13555-024-01195-z

2024-06-20

Dermatology and Therapy

Abstract:Palmoplantar pustulosis (PPP) is a pruritic, painful, chronic dermatitis that greatly impacts functioning and quality of life and can be difficult to treat. Approved treatment options for PPP are limited, and many patients do not fully respond to current treatments.

dermatology
Evaluation of hematological inflammatory parameters in patients with palmoplantar pustulosis

Xin Ning,Chao Wu,Biao Song,Hai‐Meng Wang,Hong‐Zhong Jin

DOI: https://doi.org/10.1111/ijd.17230

2024-05-13

International Journal of Dermatology

Abstract:Background Palmoplantar pustulosis (PPP) is a chronic inflammatory disease of ill‐defined etiopathology. Recent studies have proposed complete blood count‐based hematological parameters, such as neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), as biomarkers to monitor disease status in many inflammatory diseases. This study aimed to analyze for the first time the clinical significance of hematological parameters, including NLR, monocyte/lymphocyte ratio (MLR), PLR, mean platelet volume (MPV), plateletcrit (PCT), and pan‐immune‐inflammation value (PIV) in PPP patients. Methods We retrospectively investigated the clinical and laboratory data of 237 patients with PPP and 250 sex‐age‐matched healthy controls (HCs). Hematological parameters were compared between patients with PPP and HCs. The correlations between these parameters and disease severity, as well as treatment response, were analyzed. Results NLR, MLR, MPV, PCT, and PIV values were significantly higher in PPP patients than in HCs. But in receiver‐operating characteristic analyses, only monocyte count (Youden Index = 0.53), PCT (Youden Index = 0.65), and PIV (Youden Index = 0.52) performed relatively accurate distinguishment between moderate‐to‐severe cases and mild cases. PCT and PIV values were significantly correlated with disease severity. After treatment, both PIV and PCT values decreased significantly in the responder group but not in the non‐responder group. Conclusions Hematological parameters altered significantly in PPP patients. PCT and PIV can be used as simple and inexpensive biomarkers for systemic inflammation in PPP patients.

dermatology

Percutaneous transluminal angioplasty of the abdominal aorta.

Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review

Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis

A systematic review of recent randomized controlled trials for palmoplantar pustulosis

Efficacy and Safety of Benvitimod in Patients With Palmoplantar Pustulosis: An Open‐Label, Multicenter, Prospective Study

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial

Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis

Efficacy of Dupilumab in Palmoplantar Pustulosis Treatment Highlights the Role of Th2 Inflammation.

Involvement of Molecular Mechanisms between T/B Cells and IL-23: From Palmoplantar Pustulosis to Autoimmune Diseases

Interventions for chronic palmoplantar pustulosis.

Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search

The differential diagnosis of diabetic retinopathy.

Cytogenetic monitoring in CML patients treated with BMT.

Recent advances in palmoplantar pustulosis

Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis

Directivity Enhancement and Spurious Radiation Suppression in Leaky-Wave Antennas Using Inductive Grid Metasurfaces

Successful Treatment of Secukinumab-Resistant Palmoplantar Pustulosis by Dupilumab: A Case Report.

308‐nm excimer light is effective for palmoplantar pustulosis regardless of the presence or absence of focal infection: Single‐center real‐world experience of treatment for palmoplantar pustulosis

Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study

Evaluation of hematological inflammatory parameters in patients with palmoplantar pustulosis